NS Pharma, Inc.

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
See more in Biomedtracker

Latest on NS Pharma, Inc.

In Vivo

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing

 
• By David Wild

It’s a big year for Regenxbio. The company has a potential commercial launch of its gene therapy program for MPS II (Hunter syndrome), a Biologics License Application for its Duchenne muscular dystrop

Scrip

Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate

 
• By Joseph Haas, Lisa Takagi, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Apollo Licenses Ex-China Rights T

Pink Sheet

Why Sarepta’s Gene Therapy Trial Enrollment Has Been More Successful Than Its Other DMD Therapies

 
• By Derrick Gingery

The clinical trial testing Sarepta Therapeutics, Inc. ’s gene therapy candidate in Duchenne muscular dystrophy enrolled remarkably faster than the company’s studies looking at three drugs that treat

Pink Sheet

Sarepta’s DMD Gene Therapy, Like Exondys 51, Is Foundational, Advocates Argue

 
• By Derrick Gingery

Just as they did with Sarepta Therapeutics, Inc. ’s Exondys 51 (eteplirsen), patient groups view the company’s gene therapy candidate in Duchenne muscular dystrophy as a foundation to unlock more inv